Newlin Investment Company

Sharp Edge Labs, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of biosensors for drug discovery and cellular biology research. The company creates Fluorogenic Activating Modules (FAMs) that enable accurate detection of cellular trafficking, facilitating high-throughput screening and subsequent analysis. Its offerings include single-chain antibody fragments that activate fluorescence in specially designed dyes, assays for receptor internalization, and fluorogenic sensor dyes. Sharp Edge Labs focuses on addressing monogenic diseases, trafficking defects, and patient-driven discovery, with specific programs aimed at correcting trafficking defects in conditions such as cystic fibrosis and Parkinson's disease, as well as addressing lysosomal storage disorders. Originally known as Sharp Edge Technologies, Inc., the company was incorporated in 2010.

SpIntellx, Inc. is a computational and systems pathology company based in Pittsburgh, Pennsylvania, that specializes in spatial intelligence software products designed for analyzing pathology tissue sections in cancer diagnosis. Founded in 2017, the company offers innovative solutions such as SpIntellx, which processes image data sets from various imaging platforms and reagents, and HistoMapr, a computational guide for pathologists. Additionally, TumorMapr is utilized to analyze the spatial interactions of biomarkers within whole slide images using multiplexed fluorescence. With a focus on Precision Pathology and Spatially Intelligent Biology, SpIntellx leverages unbiased spatial analytics powered by explainable AI to enhance understanding of complex cancer biology, thereby facilitating advancements in drug development, diagnostics, and treatment strategies.

C2Sense, Inc., founded in 2013 and based in Cambridge, Massachusetts, specializes in developing chemiresistive gas sensors for applications in food and agriculture. Their sensors are designed to detect gases such as ethylene and biogenic amines at low concentrations, monitoring fruit ripeness and the freshness of meat, fish, and poultry throughout the supply chain. This technology helps improve food quality and reduce waste by enabling informed decisions at every stage from growers to consumers. Additionally, C2Sense is working on Halo Diagnostics, a digitally connected immunoassay reader that provides near-PCR sensitivity for patient-to-provider workflows. The company also offers sensing solutions for product quality information and counterfeit detection, using molecular additives that can be integrated into products or packaging to provide real-time status updates and detect issues during distribution.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Sharp Edge Labs, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of biosensors for drug discovery and cellular biology research. The company creates Fluorogenic Activating Modules (FAMs) that enable accurate detection of cellular trafficking, facilitating high-throughput screening and subsequent analysis. Its offerings include single-chain antibody fragments that activate fluorescence in specially designed dyes, assays for receptor internalization, and fluorogenic sensor dyes. Sharp Edge Labs focuses on addressing monogenic diseases, trafficking defects, and patient-driven discovery, with specific programs aimed at correcting trafficking defects in conditions such as cystic fibrosis and Parkinson's disease, as well as addressing lysosomal storage disorders. Originally known as Sharp Edge Technologies, Inc., the company was incorporated in 2010.

Machine Translation answers the need of today’s global business for high volume and high velocity content localization and enterprise translation. Safaba provides Enterprise Machine Translation solutions to the world’s leading global enterprises.

Liquid X is an innovative electronic company specializing in the development of functional, particle-free metallic inks that enable the printing of metal traces and films with performance comparable to bulk metal. The company collaborates with manufacturers in the electronics industry to create and print components for a variety of applications, including sensors, heating elements, and smart textiles. Liquid X's inks are distinct in that they contain actual metal atoms, rather than nanoparticles or metal flakes, which results in superior metal film properties. The inks offer low conversion temperatures and short processing times, allowing for the use of diverse substrates, ranging from paper and gauze to flexible plastics. Furthermore, the low viscosity of Liquid X's inks facilitates multiple deposition methods, including inkjet, slot die, flexography, offset, and gravure, making them suitable for a wide array of emerging niche applications in the electronics sector.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Plextronics is a company that specializes in printed electronics, particularly in the development of organic light-emitting diode (OLED) displays and lighting. The company focuses on innovative technologies involving conductive inks and associated processes, which are essential for the mass production of printed electronic devices. Additionally, Plextronics is involved in the development of active layer technology for organic solar cells and plastic circuitry. By advancing these technologies, Plextronics aims to reduce production costs and enhance the feasibility of integrating printed electronics into various applications.